-
Sector Analysis
Clostridioides difficile Infections (CDI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in CDI Therapeutics. In 2024, there were more than 2.04 million diagnosed incident cases of CDI in the 16 countries covered in GlobalData’s epidemiology forecast. The current CDI market is dominated by several companies marketing genericized antibiotic therapies. The CDI pipeline holds 48 molecules, with five molecule present in Phase III development. Over the past 10 years, commercial sponsors headed trials for CDI, led by Pfizer (seven...
-
Sector Analysis
Chronic Hepatitis B (CHB) Epidemiology Analysis and Forecast to 2034
Chronic hepatitis B (CHB) is a liver disease caused by the hepatitis B virus (HBV). HBV is transmitted via blood, semen, and other body fluids, and is commonly spread through sexual contact, needle sharing, accidental needlesticks, and vertically from a pregnant person to the newborn (Mayo Clinic, 2024). HBV infection can be prevented with a vaccine. For most people, HBV infection is a short-term, acute illness resulting in a full recovery in less than six months. For others, infection lasts...
-
Sector Analysis
Paraguay and Panama Update Drug Pricing Methodology and Advance Towards International Reference Pricing
Paraguay and Panama are the latest countries in Latin America to have modernized and updated their drug pricing methodologies by finally adopting generalized International Reference Pricing (IRP) schemes.
-
Sector Analysis
Eosinophilic Esophagitis (EoE) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2030
This report covers the US and provides an Excel-based forecast model for the EoE market through 2030. The current standard of care for EoE includes proton pump inhibitors, swallowed topical corticosteroids, and dietary elimination approaches. While biologics such as dupilumab have introduced new options, many patients experience partial response, relapse upon treatment discontinuation, or challenges with long-term adherence to dietary regimens. The US EoE market is expected to grow to $1.2B, driven by the introduction of biologics and the late-stage...
-
Sector Analysis
Plaque Psoriasis in 68 Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2030
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Plaque Psoriasis (PsO) market through 2030. GlobalData estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $30.1 billion, representing a compound annual growth rate (CAGR) of 10.0% over the 10-year forecast period. Major drivers of growth in the PsO market over the forecast period include a steady...
-
Sector Analysis
Plaque Psoriasis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030
This report covers the 7 major markets and provides an Excel-based forecast model for the Plaque Psoriasis market through 2030. GlobalData estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $30.1 billion, representing a compound annual growth rate (CAGR) of 10.0% over the 10-year forecast period. Major drivers of growth in the PsO market over the forecast period include a steady increase...
-
Sector Analysis
Parkinson's Disease in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. Across the 68 markets, sales in the Parkinson's Disease market were $5.1 billion in 2023, growing to $10.1 billion in 2033. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 66.0% and 69.6% of 68-market sales in 2023 and 2033, respectively.
-
Sector Analysis
CRISPR Gene Editing in Infectious Diseases: Market Overview, Pipeline Products, Clinical Trials, Challenges, Deals, Companies and Future Outlook
The report provides an overview of the potential of CRISPR-based therapeutics in the infectious disease space. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a precision gene-editing tool that enables targeted modification of DNA. It uses a guide RNA to direct a Cas enzyme (such as Cas9 or Cas12) to a specific genetic sequence, where it creates a cut and allows for the insertion, deletion, or correction of DNA. In infectious diseases, CRISPR may be used to directly disrupt viral...
-
Sector Analysis
Respiratory Syncytial Virus Prophylaxis in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030
The report provides an in-depth assessment of the RSV prophylaxis market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook. RSV is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) orthopneumovirus belonging to the Pneumoviridae family. The most common clinical scenario for RSV is an upper respiratory tract infection (URTI), which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract...
-
Thematic Analysis
FDI Trends in North America (2025)
Canada’s FDI outlook remains rife with economic uncertainty, being intrinsically linked to the US. According to GlobalData’s FDI Database, the US constitutes approximately 45% of the 371 (announced) FDI projects in Canada’s inward FDI pipeline (from 2023 to close of Q2 2025). Prime Minister Mark Carney initially adopted a tough rhetoric, indicating a desire to renegotiate the USCMA trading agreement. Though, the current state-of-play reads that Canada has filed a WTO dispute contesting US tariff obligations, while elevated 35% tariffs...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.